It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company’s lead program is GH001 ...

Guggenheim initiated coverage of GH Research (GHRS) with a Buy rating and $32 price target The firm’s thesis on GH is based around the belief that rapid-acting psychedelics like 5-MeO-DMT have the ...

Fintel reports that on March 13, 2025, Guggenheim initiated coverage of GH Research (NasdaqGM:GHRS) with a Buy recommendation ...

GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression. Fintel is one of the most ...

Interestingly, despite the molecular similarity between DMT and its derivative 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), they have distinct characteristics. Both cause ego dissolution and time ...

GH Research PLC (NASDAQ:GHRS) is a biopharma company working on psychiatric and neurological disorders by developing novel and proprietary mebufotenin (5-MeO-DMT) therapies for conditions like ...

or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

It focuses on 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments. Its lead program, GH001 (inhalable mebufotenin), is in Phase 2 clinical trials for treatment-resistant depression ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. First dates are just the beginning, and many of us would not handle past experiences the same way now as we did then. Get up ...

This important study investigates thalamocortical communication and cross-frequency coupling in human and animal models under anesthesia, seizures, and the effects of the serotonergic psychedelic ...

Feb 1, 2025 - Xbox's ambitious multi-platform plans have begun and while Forza is the first big Xbox exclusive to hit PS5, it likely won't be the last.